The authors declare that they have no competing interests.
FMS was responsible for the study design, clinical assessment, analysis, communication of data and drafting the manuscript. YCC was responsible for the study design and the generation, analysis, communication of data and critical revision of important intellectual content. BH was responsible for the study design, clinical assessment, analysis, communication of data and critical revision of important intellectual content. TTC was responsible for the statistical design, data analysis and critical revision of important intellectual content. WCL was responsible for study design, analysis of data and critical revision of important intellectual content. CCL was responsible for the study design, served as the clinical coordinator, and performed data analysis, critical revision of important intellectual content. All authors read and approved the final manuscript.
Osteoporotic fractures are associated with mortality in postmenopausal woman. Whether raloxifen treatment after vertebroplasty can reduce mortality is unclear in this group. To compare the effect of raloxifene and no osteoporosis treatment on the risk of mortality after vertebroplasty, we designed this study.
This was a retrospective study (January 2001 to December 2007). Follow-up for each participant was calculated as the time from inclusion in the study to the time of death, or to December 31st, 2013, whichever occurred first. All of the patients underwent baseline bone density studies, and age and body mass index (kg/m2) were recorded. All associated medical diseases such as diabetes, hypertension, and liver and renal disease were recorded.
One hundred and forty-nine patients with vertebral fractures were enrolled, of whom 51 used raloxifene and 98 patients did not receive any anti-osteoporotic therapy. At the end of the follow-up period, 62 patients had died and 87 were still alive. The treated patients had a lower mortality rate than those who did not receive treatment (P = 0.001, HR = 3.845, 95 % CI 1.884-7.845). The most common cause of mortality was sepsis, and those who received raloxifene had a lower rate of sepsis compared to those who did not receive treatment (P < 0.001).
Effective treatment with raloxifene may had a lower mortality rate in patients with postmenopausal osteoporosis-related vertebral fractures after vertebroplasty.
Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Jama. 1999;282(7):637–45. CrossRefPubMed
Lufkin EG, Whitaker MD, Nickelsen T, Argueta R, Caplan RH, Knickerbocker RK, et al. Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J Bone Miner Res Off J Am Soc Bone Miner Res. 1998;13(11):1747–54. CrossRef
Cooper C, Atkinson EJ, Jacobsen SJ, O'Fallon WM, Melton 3rd LJ. Population-based study of survival after osteoporotic fractures. Am J Epidemiol. 1993;137(9):1001–5. PubMed
Turner CH, Sato M, Bryant HU. Raloxifene preserves bone strength and bone mass in ovariectomized rats. Endocrinology. 1994;135(5):2001–5. PubMed
Brown JP, Josse RG. clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2002. 2002;167(10 Suppl):S1–34.
Hajcsar EE, Hawker G, Bogoch ER. Investigation and treatment of osteoporosis in patients with fragility fractures. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2000;163(7):819–22. PubMed
Freedman KB, Kaplan FS, Bilker WB, Strom BL, Lowe RA. Treatment of osteoporosis: are physicians missing an opportunity? J Bone Joint Surg Am. 2000;82-A(8):1063–70. PubMed
Hasserius R, Karlsson MK, Nilsson BE, Redlund-Johnell I, Johnell O. Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: a 10-year population-based study of 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis Study. Osteoporos Int. 2003;14(1):61–8. CrossRefPubMed
Jalava T, Sarna S, Pylkkanen L, Mawer B, Kanis JA, Selby P, et al. Association between vertebral fracture and increased mortality in osteoporotic patients. J Bone Miner Res Off J Am Soc Bone Miner Res. 2003;18(7):1254–60. CrossRef
Nguyen ND, Ahlborg HG, Center JR, Eisman JA, Nguyen TV. Residual lifetime risk of fractures in women and men. J Bone Miner Res Off J Am Soc Bone Miner Res. 2007;22(6):781–8. CrossRef
- Is raloxifene associated with lower risk of mortality in postmenopausal women with vertebral fractures after vertebroplasty?: a hospital-based analysis
- BioMed Central
Neu im Fachgebiet Orthopädie und Unfallchirurgie
Mail Icon II